Parkinson's Flashcards
MOAb Inhibitors
- Rasagiline
- Selegiline
MOA:
Stop dopamine from being degraded in the pre-synaptic neurons (Conversion from dopamine to DOPAC) + protect residual dopamine vs oxidation
COMT Inhibitors
- Entacapone
- Tolcapone
MOA:
Stop dopamine degradation from DOPAC to Homovanillic acid.
(!) May alleviate dystonias and motor fluctuations in long-term management of L-DOPA.
Optimises effect of L-DOPA when used in combination
Increasing dopamine release
• Amantadine
MOA:
Inhibition of amine uptake, inhibition of MOA activity, release of dopamine (and noradrenaline) from monoaminergic terminals.
Increasing dopamine synthesis
• L-DOPA/Levodopa
MOA: Dopaminergic nerve fibres take up L-DOPA. Converted by the enzyme DOPA decarboxylase to dopamine.
• Madopar (has PDCI Benserazide)
MOA: Contains peripheral decarboxylase inhibitor (PDCI) along with L-DOPA to prevent the conversion to dopamine to occur outside the BBB (causes nausea/vomiting due to stimulation of the chemoreceptor trigger zone).
Other PDCIs include carbidopa
Side effects: • Nausea/vomiting • Postural hypotension • Psychosis • Impulse-control disorders • Excessive day-time sleepiness
Motor complications:
“On-off” effect
“Wearing-off” (“end-of-dose” deterioration)
Dyskinesia, dystonia
Post synaptic dopamine receptor agonists
- Rotigotine (!) (ropinirole, pramipexole) - non-selective, has recently been introduced. It can be given as a transdermal patch (continuous administration over 24hrs)
- Apomorphine - Non-selective potent emetic: that can be given as infusion.
- Bromocriptine - Much higher affinity for D1 than D2, also used for other types of infertility.
- Pergolide, Quinpirole - Show little selectivity between D1 and D2 families of receptors.
Anticholinergics
• Orphenadrine, procyclidine, trihexyphenidyl
MOA: Dopamine loss leads to hyperactivity of cholinergic cells.
They increase dopamine release, inhibit dopamine re-uptake, inhibit overactivity.
Side Effects: dry mouth, flushed (hot) skin, dilation of pupils, tachycardia etc…